GlassScriptPhysician profile
Shalin Shah
NPI 1215324462
$9,084.41
in general payments reported to CMS, 2019-2025
55 companies · $2,525 in 2025
The $2,525 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $257 · 2022: $1,464 · 2023: $3,192 · 2024: $1,646 · 2025: $2,525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,008 · Consulting Fee: $1,607 · Education: $749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,007.58 |
| Consulting Fee | $1,606.50 |
| Education | $749.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $1,106.10 | 2022-2025 | Datroway, Enhertu |
| Geron Corporation | $795.90 | 2025 | Rytelo |
| Avyxa Pharma, LLC | $794.23 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $571.97 | 2022-2024 | Calquence, Andexxa, Imfinzi |
| Lilly USA, LLC | $459.01 | 2022-2024 | Jaypirca, Verzenio, Omvoh |
| Novartis Pharmaceuticals Corporation | $443.73 | 2022-2025 | |
| Seagen INC. | $409.82 | 2021-2023 | Padcev, Adcetris, Tukysa |
| Astellas Pharma US INC | $333.05 | 2022-2024 | Padcev, Xtandi |
| Genentech USA, INC. | $318.01 | 2021-2025 | Tecentriq, Lunsumio, Venclexta |
| Incyte Corporation | $312.53 | 2022-2024 | Jakafi, Monjuvi |
| Merck Sharp & Dohme LLC | $284.70 | 2022-2024 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $221.83 | 2022-2025 | Tecvayli, Darzalex, Tremfya |
| Amgen INC. | $221.12 | 2021-2023 | Lumakras |
| Pfizer INC. | $209.47 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $200.31 | 2022-2024 | Opdivo, Opdualag |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $197.16 | 2022-2024 | |
| Abbvie INC. | $182.85 | 2023-2025 | Venclexta |
| Gilead Sciences, INC. | $176.37 | 2022-2025 | Trodelvy |
| Beone Medicines USA, INC. | $138.03 | 2025 | Tevimbra, Brukinsa |
| Genzyme Corporation | $130.59 | 2022-2024 | |
| Celgene Corporation | $119.30 | 2022-2025 | Pomalyst, Reblozyl |
| Beigene USA, INC. | $108.63 | 2023-2025 | Brukinsa, Tevimbra |
| G1 Therapeutics, INC. | $107.58 | 2022-2023 | Cosela |
| Takeda Pharmaceuticals U.S.A., INC. | $97.46 | 2023-2024 | Fruzaqla, Iclusig, Ninlaro |
| Alexion Pharmaceuticals, INC. | $85.16 | 2022-2024 | Ultomiris |
| Regeneron Healthcare Solutions, INC. | $83.62 | 2022-2023 | Libtayo |
| Jazz Pharmaceuticals INC. | $71.25 | 2023-2024 | |
| Mirati Therapeutics, INC. | $70.49 | 2023 | Krazati |
| Tersera Therapeutics LLC | $66.32 | 2023-2025 | Xermelo, Zoladex |
| Coherus Oncology, INC. | $62.73 | 2021-2024 | |
| Array Biopharma INC | $49.62 | 2022-2023 | Talzenna, Inlyta, Xtandi |
| Exelixis INC. | $45.19 | 2022-2023 | Cabometyx |
| Emd Serono, INC. | $44.84 | 2023-2025 | Tepmetko |
| Servier Pharmaceuticals LLC | $43.85 | 2023-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $43.25 | 2023 | Imbruvica |
| Bayer Healthcare Pharmaceuticals INC. | $40.19 | 2023-2024 | |
| Ipsen Biopharmaceuticals, INC | $39.13 | 2023 | Somatuline Depot, Onivyde, Tazverik |
| Kite Pharma, INC. | $37.39 | 2023 | Yescarta |
| Sobi, INC | $35.97 | 2023 | |
| Medtronic, INC. | $35.88 | 2021 | |
| Blueprint Medicines Corporation | $26.09 | 2023 | Ayvakit |
| Adaptive Biotechnologies Corporation | $24.00 | 2023 | Clonoseq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.60 | 2025 | |
| Dendreon Pharmaceuticals LLC | $22.43 | 2024 | Provenge |
| Kyowa Kirin, INC. | $20.98 | 2022 | |
| Telix Pharmaceuticals | $19.83 | 2023 | Illuccix |
| Lundbeck LLC | $19.69 | 2023 | Vyepti |
| Puma Biotechnology, INC. | $18.35 | 2024 | |
| Apellis Pharmaceuticals, INC. | $18.14 | 2024 | Empaveli |
| Aveo Pharmaceuticals, INC. | $17.68 | 2022 | |
| Janssen Pharmaceuticals, INC | $17.44 | 2023 | Xarelto |
| Taiho Oncology, INC. | $17.21 | 2023 | |
| Cti Biopharma Corp. | $16.24 | 2022 | |
| Glaxosmithkline, LLC. | $15.64 | 2022 | |
| Novo Nordisk INC | $13.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shalin Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.